Tag Archives: FDA

Mayo Clinic Reports Solid 2012 Financial Performance


Mayo Clinic today reported a solid 2012 financial performance as it works to provide high-quality care at lower cost, strengthen its destination medical center practice and deliver expertise to patients and physicians in new ways. Mayo Clinic reported annual revenue … Continue reading

By Karl Oestreich | Posted in Cancer, Cardiology & Cardiac Surgery, Transplant, Uncategorized, Urology | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Federal Court issues ruling on drug- and device-company marketing of off-label drugs


From the New York Times today: “In a case that could have broad ramifications for the pharmaceutical industry, a federal appeals court on Monday threw out the conviction of a sales representative who sold a drug for uses not approved … Continue reading

By nickhanson | Posted in Education, Government Relations, Health Care Delivery Science, Health Policy, Research, Uncategorized | Tagged , , , , , | Leave a comment

Mayo Gets FDA Approval for New Imaging Agent for Recurrent Prostate Cancer


Evaluating men for prostate cancer recurrence has long been a major challenge; physicians have had to wait until a patient’s prostate-specific antigen, or PSA, levels rose to values between 20-30 ng/mL to identify sites of recurrent prostate cancer. Mayo Clinic … Continue reading

By joedangor | Posted in Cancer, Innovation, Radiology, Urology | Tagged , , , , , , | Leave a comment

Mayo Makes Recommendations to Patients Taking Simvastatin Therapy


The Food and Drug Administration last week released a warning last week about using a high dose of the cholesterol-lowering medication simvastatin (Zocor), as a result of concerns about muscle damage. Mayo Clinic’s recommendations to patients are the same as … Continue reading

By Traci Klein | Posted in Cardiology & Cardiac Surgery | Tagged , , , , | Comments (2)